Select Page

Anti-Human CD279 (PD-1) (Nivolumab) – PE – 50 µg

50 µg



ApplicationFA, FC, IHC
ConjugateR-phycoerythrin (PE)
IsotypeHuman IgG1κ
ImmunogenHuman PD-1
Species ReactivityHuman, Cynomolgus Monkey
FormulationThis R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Research AreaCancer, Immunology
Description/BackgroundProgrammed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
Storage TemperatureThis R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
ProtocolsFA, FC, IHC
Clone Number5C4.B8
Concentration0.2 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
50 µg